Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Pediatric Hematology/Oncology
•
Neurology
•
Child Neurology
•
Pediatric Oncology
•
Neurodevelopmental Disabilities
Would you recommend a specific workup or change in management for patients with severe, persistent deficits from methotrexate leukoencephalopathy?
Related Questions
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
What workup do you consider for a developmentally typical child with multiple large café au lait macules but no other signs of neurofibromatosis?
How do you counsel parents of patients with Autism Spectrum Disorder regarding the limitations of medications without engaging in behavioral or family interventions?
How do you decide when to pursue genetic testing for cerebral palsy?
What pharmacological management do you consider in patients with Autism Spectrum Disorder whose primary behavior is aggression?
What behavioral interventions have you found most effective for managing self-injurious behavior in autism?
When do you consider testing with stroke gene panels in young stroke patients?
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
Would you recommend muscle or nerve biopsy in a patient with amyoplasia congenita?
What factors do you consider when determining eligibility for hematopoietic stem cell therapies for metachromatic leukodystrophy?
